{"retracted":false,"update":{"timestamp":1460073600000,"doi":"10.1007/s11523-016-0433-x","type":"correction"},"doi":"10.1007/s11523-015-0369-6","journal":"Targeted Oncology","publisher":"Springer Nature","title":"Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy"}
